Synergy Pharmaceuticals Director Acquires $14,420 in Stock (SGYP)
Synergy Pharmaceuticals (NASDAQ:SGYP) Director John P. Brancaccio purchased 3,500 shares of Synergy Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average price of $4.12 per share, with a total value of $14,420.00. Following the purchase, the director now directly owns 23,944 shares in the company, valued at approximately $98,649. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Separately, analysts at Aegis raised their price target on shares of Synergy Pharmaceuticals to $28.00 in a research note on Monday, March 24th. Four investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $16.33.
Synergy Pharmaceuticals (NASDAQ:SGYP) traded up 1.20% during mid-day trading on Wednesday, hitting $4.22. The stock had a trading volume of 150,883 shares. Synergy Pharmaceuticals has a 52 week low of $3.39 and a 52 week high of $6.70. The stock’s 50-day moving average is $4.18 and its 200-day moving average is $4.93. The company’s market cap is $395.4 million.
Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.23) by $0.05. Analysts expect that Synergy Pharmaceuticals will post $-0.86 EPS for the current fiscal year.
Synergy Pharmaceuticals, Inc is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (NASDAQ:SGYP), disorders and diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.